| Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R L Giulino‐Roth, T O'Donohue, Z Chen, NL Bartlett, A LaCasce, ... British journal of haematology 179 (5), 739-747, 2017 | 131 | 2017 |
| The Harriet Lane handbook: a manual for pediatric house officers JW Custer, RE Rau (No Title), 2009 | 102* | 2009 |
| Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma SM Castellino, Q Pei, SK Parsons, D Hodgson, K McCarten, T Horton, ... New England Journal of Medicine 387 (18), 1649-1660, 2022 | 88 | 2022 |
| Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal … H Dave, MR Anver, DO Butcher, P Brown, J Khan, AS Wayne, S Baskar, ... PloS one 7 (12), e52655, 2012 | 66 | 2012 |
| Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood H Dave, M Luo, JW Blaney, S Patel, C Barese, CR Cruz, EJ Shpall, ... Molecular Therapy Methods & Clinical Development 5, 13-21, 2017 | 48 | 2017 |
| Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients AA Abraham, TD John, MD Keller, CRY Cruz, B Salem, L Roesch, H Liu, ... Blood advances 3 (14), 2057-2068, 2019 | 37 | 2019 |
| Engineering cord blood to improve engraftment after cord blood transplant RS Mehta, H Dave, CM Bollard, EJ Shpall Stem Cell Investigation 4, 2017 | 28 | 2017 |
| Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT H Kinoshita, KR Cooke, M Grant, M Stanojevic, CR Cruz, M Keller, ... Blood advances 6 (8), 2520-2534, 2022 | 27 | 2022 |
| Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents A Attarbaschi, O Abla, L Ronceray, S Bansil, S Bomken, B Burkhardt, ... Blood advances 3 (24), 4291-4297, 2019 | 25 | 2019 |
| ROR1 and ROR2—Novel targets for neuroblastoma H Dave, D Butcher, M Anver, CM Bollard Pediatric hematology and oncology 36 (6), 352-364, 2019 | 24 | 2019 |
| Novel TCR-like CAR-T cells targeting an HLA∗ 0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia S Raskin, S Van Pelt, K Toner, PB Balakrishnan, H Dave, CM Bollard, ... Molecular Therapy-Methods & Clinical Development 23, 296-306, 2021 | 19 | 2021 |
| The role of screening sinus computed tomography in pediatric hematopoietic stem cell transplant patients CA Zamora, AG Oppenheimer, H Dave, H Symons, TAGM Huisman, ... Journal of computer assisted tomography 39 (2), 228-231, 2015 | 17 | 2015 |
| Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma H Dave, M Terpilowski, M Mai, K Toner, M Grant, M Stanojevic, C Lazarski, ... Blood Advances 6 (2), 473-485, 2022 | 16 | 2022 |
| Immunotherapy for pediatric leukemia NN Shah, H Dave, AS Wayne Frontiers in oncology 3, 166, 2013 | 16 | 2013 |
| Case report: fatal complications of BK virus-hemorrhagic cystitis and severe cytokine release syndrome following BK virus-specific T-cells EM Holland, C Gonzalez, E Levy, VA Valera, H Chalfin, J Klicka-Skeels, ... Frontiers in Immunology 12, 801281, 2021 | 14 | 2021 |
| SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report KO McNerney, RM Richards, P Aguayo-Hiraldo, FG Calkoen, JA Talano, ... Journal for immunotherapy of cancer 11 (1), 2023 | 11 | 2023 |
| Driving the CAR to the bone marrow transplant program H Dave, L Jerkins, PJ Hanley, CM Bollard, D Jacobsohn Current Hematologic Malignancy Reports 14, 561-569, 2019 | 11 | 2019 |
| T-cell therapies for T-cell lymphoma K Toner, CM Bollard, H Dave Cytotherapy 21 (9), 935-942, 2019 | 11 | 2019 |
| Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults A Dreyzin, D Jacobsohn, A Angiolillo, B Wistinghausen, RJ Schore, ... Pediatric Hematology and Oncology 39 (4), 370-378, 2022 | 7 | 2022 |
| A randomized phase III trial of brentuximab vedotin (Bv) for de novo high-risk classical hodgkin lymphoma (cHL) in children and adolescents-study design and incorporation of … SM Castellino, SK Parsons, Q Pei, K McCarten, S Kessel, A Punnett, ... Klinische Pädiatrie 232 (02), S-II-07, 2020 | 4 | 2020 |
